Sunday, July 05, 2009

Osaka Fails to Report Tamiflu Resistant H1N1 Virus Mutation


An Osaka health official found a genetic mutation of swine flu that is resistant to Tamiflu on June 18 — nearly two weeks before the "first" finding was reported in Denmark — but failed to disclose it, the health ministry said Thursday.

The mutation, found in a woman in her 40s in Toyonaka who caught the H1N1 influenza A virus in May, is the first reported case of Tamiflu-resistant swine flu in Japan.

Other mutations that are resistant to Tamiflu have been found in Denmark and most recently in Hong Kong.

Remember the mutation in Brazil that was denied by the CDC and the WHO?

What is troubling is as far back as May, there have been reports from Mexico that the H1N1 virus was mutating..

Jorge Torres
El Universal
Wednesday May 13, 2009

Health Authorities of Mexico, United States and Canada detected what could be a new version or a mutation of the influenza virus A (H1N1), and not out at the moment that is more aggressive than those currently circulating in the world.

Since the epidemiological alert on April 23 and from the laboratory that was set to run the PCR, "discusses this virus keeps alerting Mexican authorities, revealed the director general of the National Center of Epidemiological Surveillance and Disease Control (Cenavece), Miguel Angel Lezana.

"We have cases where immunofluorescence says is A, but I did not say what subtype. PCR tells me that it is today we have cases like this, and this case is United States and Canada have such cases, "he says. Other officials of the Ministry of Health confirmed cases were detected which have reported a mutation or a new virus.

Lezana did not specify the number of detected infected or the states of the Republic where there were, but said that so far have been few. "Maybe they are human H1N1, H3N2 is the best, we do not know."

The director of Cenavece did not rule out that this new version of the virus is more aggressive than currently circulating. "It's a possibility, the only way to know this is a series of bioassays, and the complete sequence of the gene of the virus, which has been working, we are doing both in sequencing and in these bioassays to compare with experimental animals virulence of this virus with other influenza-like "Lezana revealed, adding:" The insulation we are getting both cases who have died and those who do not, because it is important to know whether the fact that one person dies and another not, has to do with the characteristics of a virus or other factors. "

The official said that in cases where non-subtype has been identified, all patients are alive. "

- Have you told the President?

The president is fully informed of everything.

Meanwhile, a preliminary report prepared by a multidisciplinary group of international scientists, including Mexicans, warned that the number of infected influenza A could have been widespread in Mexico at a rate higher than the Mexican authorities have acknowledged so far. According to the report published in part in the latest edition of the prestigious journal Science, have 23 thousand affected by the epidemic, very far to figure out by the authorities.

Of course the company that makes Tamiflu would diminish the importance of the mutation. And back on June 12th, I had made this post.

In that post I had stated:

So again, who had the original seed strain in Mexico and why did GlaxoSmithKline get the first contracts if it uses eggs to grow the strain?

The stories on GalxoSmithKline are B.S. My bet is they are now working on a new mutated strain of the H1N1...

London-based GlaxoSmithKline (NYSE: GSK), which has its U.S. headquarters in Research Triangle Park, said on Friday that it has begun the process of developing a new vaccine at manufacturing sites in Canada and Germany. The company expects the first doses of vaccine to be available in four to six months, subject to regulatory approval.

The fact that other companies are coming out ahead of GlaxoSmithKline would diminish the contract that was first placed with GlaxoSmithKline...

As I stated awhile back on a previous thread, why would governments contract with a company that would use a process that is, (when compared to other companies) months behind in developing a vaccine?

The fact is, Glaxo doesn't, it uses cell-based technology too.

So don't be too surprised to see news in the fall that the virus is spreading faster and the severity is getting stronger and a new vaccine is being developed...

The article on May 13th, out of Mexico is newly found since I made the June 12th post and it lends credibility that there is another mutated seed strain out there that is being worked on. And it would stand to reason that Glaxo has it.

Moreover, why does the CDC and WHO deny the mutation when in Mexico both the United States and Mexico knew it was mutating?

No comments: